Since humans with Down syndrome have three copies of DYRK1A, and since autopsy data indicate that DYRK1A protein is expressed at 50% higher levels than in normal (102, 103), one of the early goals of DYRK1A inhibitor research was developing their use in early childhood for people with Down syndrome. The gene discussed is DYRK1A; the disease is Down syndrome.